A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Trial Profile

A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2018

At a glance

  • Drugs Lacnotuzumab (Primary) ; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Jun 2018 This trial has been changed from suspended to completed in Austria, according to European Clinical Trials Database
    • 04 Apr 2018 This trial has been completed in Spain, according to European Clinical Trials Database
    • 09 Feb 2018 This trial has been suspended in Austria as per European Clinical Trials Database record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top